Journal Information
Vol. 34. Issue. 6.November 2014
Pages 693-810
Vol. 34. Issue. 6.November 2014
Pages 693-810
DOI: 10.3265/Nefrologia.pre2014.Jun.12599
Full text access
Reply to the comment on 'Acute Rejection of Non-functional renal grafts in dialysis patients after starting treatment with interferon and ribavirin'
Respuesta al comentario de «Rechazo agudo del injerto renal no funcionante en pacientes en diálisis después de iniciar tratamiento con interferón y ribavirina»
Visits
...
Teresa Cavero-Escribanoa, Enrique Morales-Ruiza
a Servicio de Nefrolog??a, Hospital Universitario 12 de Octubre, Madrid,
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics

Nefrologia 2014;34(6):676

doi:10.3265/Nefrologia.pre2010.Jun.10485

Reply to Martín-Gómez MA

Comment on Nefrologia 2014;34(6):675

Nefrologia 2014;34(2):230-4

Nefrologia 2014;34(6):676

doi:10.3265/Nefrologia.pre2014.Jun.12599

Respuesta a Martín-Gómez MA

Comentario en Nefrologia 2014;34(6):675

Nefrologia 2014;34(2):230-4

Full Text

To the Editor,

We appreciate the comments made by Dr. Martin-Gómez1 on our article “Acute rejection of non-functional renal graft in dialysis patients after starting treatment with interferon and ribavirin”. As the author notes, treatment with ribavirin (RBV) worsens anaemia in patients with chronic kidney disease, even in those with a prior kidney transplant with immunological intolerance syndrome or, as in the cases presented in our article, acute rejection after initiation of antiviral therapy with interferon (IFN), as a result of the intense inflammatory reaction triggered. Consequently, nephrologists should always pay special attention to these patients with more frequent laboratory controls, more intense treatment with erythropoietin stimulating factors and/or iron therapy and in refractory cases, blood transfusion,  which, as Dr. Martín-Gómez says in her letter, could jeopardise the future of a new transplantation due to the formation of anti-HLA antibodies.

Currently, new direct acting antiviral drugs are being tested2, some of which are already used in patients without kidney disease that have not responded to standard therapy, increasing response rate3. Telaprevir and boceprevir, NS3/4A protease inhibitors, have already been approved as antiviral salvage therapy in patients with chronic hepatitis C, genotype 1, and are being tested in clinical trials with patients with chronic terminal kidney disease4; although in the case we are addressing they would not provide any benefit, as they are administered in triple therapy with IFN and RBV, and also cause anaemia, among other side effects2,3. However, at present there are other ongoing clinical trials with new molecules such as MK-5172, an NS3/4A protease inhibitor and MK-8742, an NS5A replication complex inhibitor, which would be free of IFN and RBV and could be an interesting alternative. However, solid organ transplant recipients have, to date, b>>een excluded from these5.

Until we have the results of these clinical trials and patients with non-functioning kidney transplants participate in them, we will have to take the measures detailed in these articles1,6.

 

Conflicts of interest

 

The authors declare that they have no conflicts of interest related to the contents of this article.

Bibliography
[1]
Mart??n-G??mez MA. Comentario a ??Rechazo agudo del injerto renal no funcionante en pacientes en di??lisis despu??s de iniciar tratamiento con interfer??n y ribavirina??. Nefrologia 2014;34(6):675. [Pubmed]
[2]
Liang JT, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013;368:1907-17. [Pubmed]
[3]
Jacobson IM, McHutchinson JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16. [Pubmed]
[4]
A pilot study to treat patients with chronic hepatits C virus (HCV) genotype 1 and end stage renal disease (ESRD). Available at: www.clinicaltrials.gov.
[5]
The pharmacokinetics of MK-5172 and MK-8742 in participants with renal insufficiency. Available at: www.clinicaltrials.gov.
[6]
Cavero-Escribano T, Morales-Ruiz E, Manzano-Pe??a MT, Mu??oz-G??mez R, Hern??ndez-Mart??nez E, Guti??rrez-Mart??nez E, et al. Rechazo agudo del injerto renal no funcionante en pacientes en di??lisis despu??s de iniciar tratamiento con interfer??n y ribavirina. Nefrologia 2014;34(2):230-4. [Pubmed]
Idiomas
Nefrología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.